PubMed Health⌕ Search

Biomedical subjects

G Ueda

Publications and source records attributed to G Ueda.

At least 91 records · Page 5Linked to original sources
PubMed1986

Clinical significance of argyrophilia in endometrial carcinomas.

The clinical significance of argyrophilia in endometrial carcinomas was studied in 187 patients with the endometrioid form of adenocarcinoma. Argyrophil cells were tentatively subgrouped into two types: type I cells resembling the enterochromaffin cells and type II cells loaded with argyrophil granules in the apical portion or throughout the cytoplasm. The patients with endometrial carcinoma containing argyrophil cells were associated more frequently with hypertension and diabetes mellitus than those with usual endometrial carcinoma. In grade 1 carcinomas, argyrophilia was parallel with the frequency of metastases to lymph nodes and with the degree of myometrial invasions. Also, a life table showed a worse survival rate in grade 1 carcinomas with argyrophilia, especially of type I, than in those without it. Although argyrophilia was considered to be at least one of the minor prognostic factors, further clinicopathologic studies are needed in relation to a more proper subtyping of argyrophil cells.

Adenocarcinoma↗
PubMed1986

Hyperamylasemia associated with endometrioid carcinoma of the ovary: case report and immunohistochemical study.

Hyperamylasemia was noted in a patient with a stage I well-differentiated endometrioid adenocarcinoma of the ovary. Serum levels of amylase decreased rapidly after removal of the ovarian tumor. Immunohistochemical study revealed intracytoplasmic localization of amylase in many tumor cells. Although it was strongly suspected that the tumor cells had produced amylase in the present patient, further studies are required to be sure that amylase can be considered an important tumor marker for the endometrioid type of ovarian tumors.

Adenocarcinoma↗
PubMed1986

Immunohistochemical demonstration of amylase in endometrial carcinomas.

Cellular localization of amylase in 100 endometrial carcinomas was studied by the immunoperoxidase method using an antibody to human pancreatic amylase. Amylase activity was observed in 12 tumors, localizing in the cytoplasm of tumor cells. They were seven well-differentiated adenocarcinomas, one poorly differentiated adenocarcinoma, one papillary serous carcinoma, two mucinous carcinomas, and one adenocarcinoma with squamous differentiation. Of these, many amylase reactive cells were found in one well-differentiated adenocarcinoma, one papillary serous carcinoma, and one mucinous carcinoma. The remaining nine tumors contained a few to a moderate number of amylase reactive cells. Although serum levels of amylase were not examined in the present study, the results suggest that amylase may be a potential tumor marker for some endometrial carcinomas.

Adenocarcinoma↗
PubMed1986

[A case of amylase-producing ovarian tumor].

A 51-year-old woman with ovarian carcinoma with hyperamylasemia is reported. She was admitted to Osaka General (JNR) Hospital in July 1982. A cystic tumor was palpated in the pelvis. Serum amylase, mainly the salivary type, in electrophoresis, had increased to 1583 Smith-Roe units/dL, while the pancreas was normal on ultrasonography and CT. Chemotherapy (MFC) was performed, and laparotomy revealed bilateral ovarian tumors. Histologically, they were serous cystadenocarcinoma. Serum and urinary amylase values dropped to the normal range after chemotherapy and surgery, and varied directly with the clinical course. Immunohistochemically, amylase was demonstrated in the tumor tissue by the PAP method. In conclusion, amylase was a useful marker in the diagnosis and follow-up of the present patient.

Amylases↗
PubMed1986

Immunohistochemical demonstration of HNK-1-defined antigen in gynecologic tumors with argyrophilia.

Gynecologic tumors with argyrophilia were tested immunohistochemically for reactivity with monoclonal antibody HNK-1, which detects normal and neoplastic cells derived from the neuroectodermal and the amine-precursor-uptake and decarboxylation (APUD) systems. The tumors included six small cell carcinomas and four adenocarcinomas of the cervix; 23 adenocarcinomas of the endometrium (13 with type I and 10 with type II argyrophil cells); and 11 mucinous tumors (three benign, three borderline, and five malignant), eight endometrioid carcinomas (four with type I and four with type II argyrophil cells), and two carcinoid tumors (one insular and one strumal) of the ovary. HNK-1 reactive cells were found in almost every category of tumor: in four small cell carcinomas and two adenocarcinomas of the cervix; 11 adenocarcinomas of the endometrium (eight with type I and three with type II argyrophil cells); and four mucinous (two benign and two borderline), two endometrioid (one with type I and one with type II argyrophil cells), and two carcinoid tumors of the ovary. These cells corresponded to at least some of the type I argyrophil cells in endometrial and ovarian endometrioid carcinomas and to similar cells in mucinous and carcinoid tumors of the ovary and small cell carcinoma and adenocarcinoma of the cervix. However, the remaining type I and similar argyrophil cells and almost all type II argyrophil cells were HNK-1 negative, and some of the nonargyrophil tumor cells were HNK-1 positive. Although the significance of such discrepancies in reactivity with HNK-1 antibody remains unknown, the present results suggest that some of the gynecologic tumors with argyrophilia are related to APUDomas.

Antigens, Neoplasm↗
PubMed1986

[Immunohistological demonstration of peptide hormones and serotonin in ovarian mucinous and endometrioid tumors with argyrophil cells].

The localization of peptide hormones and serotonin in ovarian mucinous and endometrioid tumors with argyrophil cells was examined by immunohistochemistry. All of the 15 mucinous tumors had argyrophil cells which resemble the enterochromaffin cells seen in the gastrointestinal tract, and peptide hormones such as gastrin and somatostatin were found in 3 of 5 benign, in 3 of 5 borderline, and in all of 5 malignant tumors. Serotonin was found in 4 benign, 3 borderline and 2 malignant tumors. Of 19 endometrioid adenocarcinomas, type I argyrophil cells which resemble enterochromaffin cells were found in 4 tumors, type II argyrophil cells which contain argyrophil granules mainly in the apical portion or throughout the whole cytoplasm were found in 14, and mixed type cells were found in one. Somatostatin-positive cells were found only in type I cells of a tumor with mixed type argyrophil cells. Serotonin-positive cells were found in 3 tumors containing type I cells. The results obtained were discussed in the comparison with those of cervical and endometrial adenocarcinomas of the uterus. In conclusion, the present study suggests that type I or similar argyrophil cells in ovarian tumors may have endocrine activity.

Adenocarcinoma↗
PubMed1986

[The production and reactivity of the monoclonal antibody (MCA-97) to endometrial adenocarcinoma].

Spleen cells from BALB/c mouse immunized with the human endometrial adenocarcinoma cell line (ISHIKAWA) were fused with mouse myeloma cell line (NS-1) in the presence of polyethylene glycol (Mr 1000). One monoclonal antibody, MCA-97 (IgM subclass), which showed reactivity with the ISHIKAWA-cell line, was obtained by a limiting dilution technique. In a cellular enzyme-linked immunospecific assay, the MCA-97 antibody reacted with all of 7 adenocarcinoma cell lines tested. In immunoperoxidase testing of formalin-fixed paraffin-embedded sections, the MCA-97 antibody reacted with most endometrial adenocarcinomas and endometrioid adenocarcinomas of the ovary, but did not react with squamous cell carcinomas or ovarian serous adenocarcinomas. In addition, it reacted with the glandular epithelium of normal tissues, such as proliferative endometrium, fallopian tube, uterine cervix and gastrointestinal tract. The reversed passive hemagglutination method demonstrated the antigen defined by MCA-97 in the sera of 5 out of 11 patients with endometrial carcinomas, and 3 out of 4 of those with ovarian endometrioid adenocarcinomas. It was not demonstrable in sera of most normal female volunteers, or any patients with cervical squamous cell carcinomas or ovarian serous adenocarcinomas. Thus, MCA-97 is of potential clinical application in diagnostic serology and pathology.

Adenocarcinoma↗
PubMed1985

The clinical value of tissue polypeptide antigen in patients with gynecologic tumors.

Tissue polypeptide antigen (TPA) was measured by radioimmunoassay in sera from patients with various gynecologic tumors: 64 uterine myomas, 129 cervical cancers, 31 endometrial cancers, and 173 ovarian tumors (89 benign, 18 low-grade malignant (LGM) and 66 malignant tumors). Among the cervical cancer patients, the incidence of elevated TPA levels increased with stage of disease from 12% in the preinvasive stage to 67% in the advanced stage. Similarly, the TPA values were elevated in 35% of the endometrial cancer patients. Among the patients with ovarian malignancies, serum TPA was elevated in the following order: LGM cases (33%), Stage I (44%), and advanced (88%). Serum TPA values varied directly with the stage and malignancy of disease, and also correlated with the effect of treatment. However, serum TPA was elevated in 22% of the patients with uterine myoma and in 12% of those with ovarian benign tumors. The current observations demonstrate that the lack of tumor specificity of TPA limits its diagnostic value in gynecologic malignancies, but that serial measurements of this antigen appear to be useful for the evaluation of therapy and monitoring of patients.

Female↗
PubMed1985

Immunohistochemical demonstration of neuron-specific enolase in gynecologic malignant tumors.

Gynecologic malignant tumors were studied by the immunoperoxidase method for neuron-specific enolase (NSE). They included 22 argyrophil cell carcinomas of the endometrium, 6 argyrophil small cell carcinomas of the cervix, 21 argyrophil cell adenocarcinomas of the ovary (endometrioid type, 10; mucinous type, 11) and 3 ovarian carcinoids (strumal type, 2; insular type, 1). NSE was demonstrated in all cases of argyrophil small cell carcinomas of the cervix and ovarian carcinoids. On the other hand, NSE was positive only in four cases of endometrial carcinomas with argyrophil cells. Argyrophil cell adenocarcinomas of the cervix and the ovary were immunohistochemically negative for NSE. The current results suggest that argyrophil small cell carcinoma of the cervix, ovarian carcinoid, and some endometrial argyrophil cell carcinomas are related to APUDoma.

Adenocarcinoma↗
PubMed1985

Immunohistochemical study of amylase in common epithelial tumors of the ovary.

Cellular localization of amylase in various ovarian tumors was studied by the immunoperoxidase method using an antibody to human pancreatic amylase. Amylase was present in eight of 34 serous carcinomas and eight of 27 endometrioid carcinomas. However, only in one poorly differentiated serous carcinoma and two well-differentiated endometrioid carcinomas were a large number of amylase-reactive cells found. Five benign and three borderline serous tumors contained no amylase. Also, amylase was not detected in any of 34 mucinous tumors or five malignant clear cell tumors. The results obtained suggest that amylase will be a useful tumor marker, when present, for follow-up of endometrioid and serous carcinomas of the ovary.

Adenocarcinoma↗
PubMed1985

Effects of prostacyclin (PGI2) on hypoxic pulmonary vasoconstriction in the conscious adult sheep.

The effects of prostacyclin (PGI2) on alveolar hypoxic pulmonary vasoconstriction were investigated in the conscious adult sheep. In our model, hypoxia also produced increases in pulmonary arterial pressure (PPA) and pulmonary vascular resistance (PVR), indicating pulmonary vasoconstriction. PGI2 was injected rapidly as a 0.5 microgram/kg bolus via the right atrium in five sheep during normoxia and hypoxia. During normoxia, PGI2 increased PPA and cardiac output, and decreased systemic arterial pressure (PSA), systemic vascular resistance (SVR) and PVR. Left atrial pressure did not change. During hypoxia following PGI2 administration, PPA decreased, CO increased, and PVR decreased, suggesting dilator action on the pulmonary resistance vessels. As the same time PSA and SVR decreased, suggesting dilator action on the systemic resistance vessels. However, the degree of the decline in PVR caused by PGI2 was much greater during hypoxia than during normoxia. The decreases in PSA and SVR induced by PGI2 were not significant between hypoxia and normoxia. These findings confirm that PGI2 decreases pulmonary and systemic vascular resistances in normoxic and hypoxic sheep. Moreover, during hypoxia, associated with the increased PPA and PVR, the administration of PGI2 appears to be particularly effective in "normalizing" these parameters.

Animals↗
PubMed1985

A clinicopathologic study of endometrial carcinoma with special reference to new histological variants.

The clinical and pathological features of 229 patients with endometrial carcinoma were analyzed with special reference to new histological variants. Histologically, 187 endometrial carcinomas were endometrioid form of adenocarcinoma, 10 mucinous carcinoma, 8 papillary serous carcinoma, 5 clear cell carcinoma, 1 secretory carcinoma, and 18 adenocarcinoma with squamous differentiation. Of these, papillary serous carcinoma was found to be a highly malignant form of endometrial carcinoma. Clear cell carcinoma was also associated with a poor prognosis. No fatal cases were observed in patients with mucinous carcinoma, secretory carcinoma, and adenocarcinoma with squamous differentiation. Patients with endometrioid form of adenocarcinoma were prognostically in between. Analysis of the patients with poor prognosis revealed that the length of time between onset of symptoms and surgery was not related to surviving periods and other prognostic factors such as clinical stage, histological grade, and myometrial invasion.

Adenocarcinoma↗